Lyon, France-based Poxel, a biopharmaceutical company developing drugs to treat type 2 diabetes, has named Richard N Kender to its board of directors as an independent board member. Most recently Mr Kender was senior vice-president of business development and corporate licensing at Merck & Co.
Richard Kender joins Poxel's board of directors
Lyon, France-based Poxel, a biopharmaceutical company developing drugs to treat type 2 diabetes, has named Richard N Kender to its board of directors as an independent board member. Most recently Mr Kender was senior vice-president of business development and corporate licensing at Merck & Co.
More from Alimentary/Metabolic
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
Novo’s semaglutide has shown its benefits as an injectable in patients with peripheral arterial disease and as an oral agent in cardiovascular outcomes, but stronger results are expected soon from Lilly’s tirzepatide.
• By
The obesity market leader has unveiled its second deal in days, paying $75m upfront for a potential first-in-class ACSL5 inhibitor, while the deal also provides some respite for Lexicon.
• By
The company is planning to launch oxylanthanum carbonate for chronic kidney disease patients on dialysis with hyperphosphatemia.
More from Therapy Areas
• By
Seeking cell therapy approaches to cure type 1 diabetes, Vertex abandons a candidate encapsulated to avoid immune system detection but hopes to file another candidate for approval in 2026.
• By
A Phase III trial testing the cortisol modulator showed a benefit on PFS and OS in patients with platinum-resistant ovarian cancer.
• By
The UK giant is forecasting peak sales of $5bn plus